Measurement of cell kinetics in cervical tumours using bromodeoxyuridine.
The pre-treatment cell kinetics of 120 cervical tumours were assessed following the in vivo labelling with the thymidine analogue Bromodeoxyuridine (BrdUrd). In 89% both static and temporal kinetic parameters could be measured. Through the analysis of multiple biopsies from each tumour marked intra tumour heterogeneity was demonstrated. The median values for the most highly labelled sample analysed for each tumour were; S-phase duration (Ts) 12.1 h, BrdUrd labelling index (CLI) 9.5% and potential tumour doubling time 4.4 days. There was a significant elevation in CLI, but no difference in Ts, between tumour and non-neoplastic cervical tissue. There was a significant elevation in CLI, advanced stage and large size tumours. Although a significant elevation in CLI was found in aneuploid tumours this is likely to represent the systemic bias of the calculation methods, with no difference being seen between aneuploid and diploid tumours when BrdUrd labelling was measured with-out reference to the nuclei DNA content. The majority of these patients were treated with radiotherapy and cell kinetic data will be correlated with treatment response when adequate follow up has been achieved.
Bolger
B S
BS
University Department of Surgery, Glasgow Royal Infirmary, UK.
Cooke
T G
TG
Symonds
R P
RP
MacLean
A B
AB
Stanton
P D
PD
D000328:Adult; D000367:Age Factors; D001706:Biopsy; D001973:Bromodeoxyuridine; D002453:Cell Cycle; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D007700:Kinetics; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011003:Ploidies; D016196:S Phase; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery
D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine